SPY335.57+0.00 0.00%
DIA278.14+0.00 0.00%
IXIC10,968.36+0.00 0.00%

BioNTech shares are trading higher after the company and Pfizer commenced a Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA candidate from their BNT162 mRNA-based vaccine program, against SARS-CoV-2.

Benzinga · -